<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445549</url>
  </required_header>
  <id_info>
    <org_study_id>070061</org_study_id>
    <secondary_id>07-C-0061</secondary_id>
    <secondary_id>070061</secondary_id>
    <nct_id>NCT00445549</nct_id>
  </id_info>
  <brief_title>Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Vandetanib is a drug that attacks a group of proteins on the surface of many cells,
           especially blood vessel cells and tumor cells.

        -  Tumors require the development of new blood vessels in order to grow and spread.

        -  In laboratory experiments, vandetanib slowed the growth of certain tumors and regulated
           their blood vessel growth.

        -  In early clinical trials, some patients' tumors did not grow for a period of time while
           they were receiving vandetanib.

      Objectives:

        -  To determine whether vandetanib can cause tumors to shrink or stabilize in some patients
           with ovarian cancer, fallopian tube cancer or primary peritoneal cancer.

        -  To determine, by tumor biopsy, if features of the tumor change with vandetanib treatment
           may predict if the tumor will likely respond to vandetanib.

      Eligibility:

        -  Women 18 years of age and older with ovarian, fallopian tube or primary peritoneal
           cancer that does not respond to standard treatment.

      Design:

        -  Patients take vandetanib daily, by mouth in 28-day cycles until their disease worsens or
           they develop unacceptable side effects.

        -  Tumor biopsies (surgical removal of a sample of tumor tissue) are done before starting
           vandetanib treatment and after 6 weeks of treatment.

        -  Patients are followed in the clinic every 4 weeks during treatment for a physical
           examination, blood tests, and review of laboratory studies and side effects.

        -  Patients have a computed tomography (CT) scan every 8 weeks to monitor tumor growth and
           magnetic resonance imaging (MRI) before starting vandetanib treatment, on the third day
           after taking vandetanib and 6 weeks into treatment.

        -  Patients quality of life is assessed with regularly scheduled questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Epithelial ovarian cancer requires neovascularization for growth and metastasis.
           Anti-angiogenesis agents have been shown to have promise in the treatment of recurrent
           disease. Expression of vascular endothelial growth factor 2 (VEGFR2) and epidermal
           growth factor receptor (EGFR) has been demonstrated in ovarian cancer specimens in
           stroma and tumor. Blocking autocrine and paracrine loops acting through these receptors
           may inhibit downstream phosphorylation targets in the mitogen activated protein kinase
           (MAPK) and AKT pathways, thereby influencing disease progression and patient outcome.

        -  The multi-kinase inhibitor ZD6474 (vandetanib, AstraZeneca, Zactima) blocks angiogenesis
           by targeting VEGFR2, and shows in vitro activity against a number of other receptor
           tyrosine kinases including resonance energy transfer (RET), vascular endothelial growth
           factor 3 (VEGFR3) and EGFR.

        -  Clinical efficacy of ZD6474 (vandetanib) in women with refractory or relapsed epithelial
           ovarian cancer is unknown, but preclinical data suggests potential value.

        -  The maximum tolerated dose of ZD6474 (vandetanib) has been determined at 300mg/day,
           limited by the dose-responsive adverse effect of prolonged (Q wave, T wave)QT interval.

      Objectives:

        -  To assess the clinical activity (CR - complete response, PR - partial response, or
           disease stabilization) of the VEGFR2 inhibitor ZD6474 (vandetanib), 300mg/d, in women
           with ovarian, fallopian tube or primary peritoneal cancer.

        -  To study target signal events: quantity and activation of VEGFR2, EGFR, AKT and
           extracellular signal-regulated kinases (ERK).

      Eligibility:

        -  Women with biopsy-proven epithelial ovarian, fallopian tube or primary peritoneal cancer
           that is relapsed and/or refractory to prior therapy.

        -  Women must have measurable disease by NCI Response Evaluation Criteria in Solid Tumors
           (RECIST) criteria and a sentinel lesion adequate for core biopsy through percutaneous
           biopsy.

        -  Women must have had no more than four prior treatment regimens.

      Design:

        -  Women will receive 300mg of ZD6474 (vandetanib) daily, orally in 28-day cycles until
           disease progression, excessive toxicity, or withdrawal from study.

        -  Biopsy of tumor will be performed prior to starting ZD6474 (vandetanib) and after six
           weeks of treatment. The quantity of phosphorylated VEGFR2, EGFR, ERK and AKT in the
           biopsy tissue will be analyzed.

        -  Clinical outcome and toxicity will be measured and correlated with target inhibition.

        -  Women will also undergo serial imaging with dynamic contrast-enhanced MRI to estimate
           tumor blood flow.

        -  Research blood samples will be taken to assess changes in circulating cytokine
           concentrations.

        -  Quality of life will be assessed during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study closed because of inadequate early activity.
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as complete response (CR), partial response (PR), or disease stabilization lasting 6 months or longer per RECIST criteria. CR-total disappearance of all evaluable disease. PR-&gt;30% reduction in the sum of the longest diameters (LD) of target lesions. Stable disease (SD) is &lt;30% decrease and &lt;20% increase in the sum of the LD of all target lesions. See the protocol Link module for full RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Adverse Events</measure>
    <time_frame>22 months</time_frame>
    <description>Here are the total # of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Vandetanib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg daily oral dose, 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>300 mg daily dose, 28 day cycle</description>
    <arm_group_label>Vandetanib treatment</arm_group_label>
    <other_name>Zactima</other_name>
    <other_name>ZD6474</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients 18 years and older with biopsy-proven epithelial ovarian, fallopian tube
             or primary peritoneal cancer that is relapsed or refractory to prior standard
             platinum-and taxane based therapy will be eligible.

          -  Histopathologic diagnosis must be confirmed in the Laboratory of Pathology (LP), NCI.
             A block of the primary or later access to recut slides is required. If this is
             unavailable, a recent resection of a metastatic site is required for entry.

          -  All patients must have measurable disease by NCI RECIST criteria and a sentinel lesion
             adequate for core biopsy through percutaneous biopsy.

          -  Patients must have a performance status of Eastern Cooperative Oncology Group (ECOG) =
             0, 1, or 2.

          -  Patients must have good end organ function:

          -  white blood cells (WBC) greater than 3000/mm(3)

          -  absolute neutrophil count (ANC) greater than 1000/mm(3)

          -  platelets greater than 150,000/mm(3)

          -  serum creatinine less than 1.5 mg/dl

          -  liver function tests (AST and ALT) within 2.5 times the upper limit of normal (ULN)

          -  bilirubin less than 1.5 mg/dl

          -  potassium between 4.0 and ULN (supplementation allowed)

          -  magnesium (Mg) and calcium (Ca) within normal limits (supplementation allowed)

          -  Systolic blood pressure less than 160 mm Hg and diastolic blood pressure less than 100
             mm Hg (therapy permitted)

          -  Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal
             therapy, and radiation therapy, alternative therapy or investigational agents).
             Carboplatin, must not have been received for at least 6 weeks prior to enrollment.

          -  Patients must have received no more than 4 prior regimens for the treatment of ovarian
             cancer.

          -  Patients must have recovered from any toxicity related to prior cancer therapy to NCI
             grade 1, except for peripheral neuropathy, which must have recovered to grade 2 or
             better.

          -  Women of childbearing age and potential must agree to use adequate barrier
             contraception (interaction with oral contraceptives is unknown) prior to study entry,
             during therapy and for 3 months after completion of therapy.

          -  Patients must be able to give written informed consent.

          -  All eligible patients must be registered by contacting Central Registration personnel
             by fax at (301) 480-0757 between the hours of 8:30am and 5:00 pm, Monday through
             Friday.

        Exclusion Criteria:

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the investigators opinion makes it undesirable for the patient to participate in
             the trial or which would jeopardize compliance with the protocol.

          -  Evidence of central nervous system (CNS) involvement (patients with abnormal clinical
             exam or history will require a head CT or MRI.

          -  History of cardiac disorders including:

          -  Clinically significant cardiac event such as myocardial infarction, New York Heart
             Association (NYHA) classification of heart disease greater than or equal to 2 within 3
             months of entry, or presence of cardiac disease that, in the opinion of the
             investigator,increases the risk of ventricular arrhythmia.

          -  Uncontrolled arrhythmia (multifocal premature ventricular contractions (PVCs),
             bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation)
             which is symptomatic.

          -  Previous history of medication-induced corrected QT interval (QTc) prolongation
             requiring discontinuation of that medication.

          -  Congenital long (Q wave, T wave) QT syndrome, or 1st degree relative with unexplained
             early sudden cardiac death(less than 40 years of age).

          -  Presence of left bundle branch block (LBBB).

          -  QTc, corrected per automated electrocardiogram (ECG) standards, that is unmeasurable,
             or greater than or equal to 480 msec on screening ECG. If a patient has QTc greater
             than or equal to 480 msec on screening ECG, the screen ECG may be repeated twice (at
             least 24 hours apart). The average QTc from the three screening ECGs must be less than
             480 msec in order for the patient to be eligible for the study.

          -  Patients requiring any concomitant treatment with medication that may cause QTc
             prolongation or induce Torsades de Pointes will not be permitted to enter this study
             unless the agent can safely be changed to one not affecting QTc.

          -  Patients requiring any concomitant treatment with medication that may inhibit
             (cytochrome p450 3A4) CYP3A4 will not be permitted to begin this study. If it is
             considered medically safe to discontinue such medication, the patient may become
             eligible once a sufficient amount of time after the last dose of such medications has
             elapsed to consider the drug adequately eliminated (at least 5 half lives of the
             drug).

          -  Patients with active infection will not be eligible, but may become eligible once
             infection has resolved and they are at least 7 days from completion of antibiotics.

          -  Patients with incomplete wound healing from previous surgery or injury will be
             ineligible. Patients must be at least 4 weeks from a major surgical procedure.

          -  Women who are actively breast-feeding will be excluded.

          -  Currently active diarrhea that is uncontrolled with medication (e.g. bulk agents or
             loperamide) that may affect the ability of the patient to absorb the ZD6474.

          -  Previous or current malignancies within the last 5 years, with the exception of
             cervical carcinoma in situ curatively treated, ductal or lobular carcinoma in situ
             curatively treated and without ongoing therapeutic intervention.

          -  No concomitant use of complementary or alternative medication or other agents
             (investigational or anti-cancer agents) will be allowed without approval of a
             principal investigator (PI) or associate investigator (AI). Every effort will be made
             to maximize patient safety and minimize changes in chronic medications.

          -  Patients with a history of deep venous thrombosis or pulmonary embolism within the
             past 3 months or those patients requiring ongoing anticoagulation will be ineligible.

          -  Patients with a history of gastrointestinal (GI) bleed or gross hematuria within the
             past 30 days will be ineligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise C Kohn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>MedlinePlus</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <link>
    <url>http://ctep.cancer.gov/protocolDevelopment/default.htm</url>
    <description>RECIST</description>
  </link>
  <reference>
    <citation>Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995 Jul;147(1):33-41.</citation>
    <PMID>7541612</PMID>
  </reference>
  <reference>
    <citation>Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004 Dec 1;22(23):4700-10. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.</citation>
    <PMID>15505275</PMID>
  </reference>
  <reference>
    <citation>Ryan AJ, Wedge SR. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer. 2005 Jun;92 Suppl 1:S6-13. Review.</citation>
    <PMID>15928657</PMID>
  </reference>
  <results_reference>
    <citation>Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12.</citation>
    <PMID>20068097</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>June 30, 2011</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2012</results_first_posted>
  <last_update_submitted>May 22, 2012</last_update_submitted>
  <last_update_submitted_qc>May 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Elise C. Kohn, M.D.</name_title>
    <organization>National Cancer Institute (NCI), National Institutes of Health (NIH)</organization>
  </responsible_party>
  <keyword>Ovarian</keyword>
  <keyword>VEGFR2</keyword>
  <keyword>EGFR</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Tyrosine Kinase</keyword>
  <keyword>Protein Phosphorylation</keyword>
  <keyword>Vandetanib</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>If 2-3 patients per month enroll onto this trial, it is expected that approximately one and a half years will be required to enroll the 35 evaluable patients required for evaluation in this study. To make an allowance for a small drop-out of patients from the study and still preserve the intended accrual goal, the total accrual will be38 patients.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib Treatment</title>
          <description>300 mg daily oral dose, 28 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib Treatment</title>
          <description>300 mg daily oral dose, 28 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.13" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Efficacy</title>
        <description>Defined as complete response (CR), partial response (PR), or disease stabilization lasting 6 months or longer per RECIST criteria. CR-total disappearance of all evaluable disease. PR-&gt;30% reduction in the sum of the longest diameters (LD) of target lesions. Stable disease (SD) is &lt;30% decrease and &lt;20% increase in the sum of the LD of all target lesions. See the protocol Link module for full RECIST criteria.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib Treatment</title>
            <description>300 mg daily oral dose, 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Efficacy</title>
          <description>Defined as complete response (CR), partial response (PR), or disease stabilization lasting 6 months or longer per RECIST criteria. CR-total disappearance of all evaluable disease. PR-&gt;30% reduction in the sum of the longest diameters (LD) of target lesions. Stable disease (SD) is &lt;30% decrease and &lt;20% increase in the sum of the LD of all target lesions. See the protocol Link module for full RECIST criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Adverse Events</title>
        <description>Here are the total # of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
        <time_frame>22 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib Treatment</title>
            <description>300 mg daily oral dose, 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Adverse Events</title>
          <description>Here are the total # of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib Treatment</title>
          <description>300 mg daily oral dose, 28 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)/CTCAE3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI::Rectum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic)::Oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Obstruction, GI::Small bowel NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Abdomen NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Chest/thorax NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Vulva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC::Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>PTT (Partial Thromboplastin Time)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Prolonged QTc interval</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Extremity-limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Joint</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Muscle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Head/headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU::Ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Obstruction, GU::Ureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GU::Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain::Pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory::Nose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reactions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other (Specify, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study closed after the first stage of accrual because of inadequate early activity with 32 cycles of administered treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elise C. Kohn, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4916</phone>
      <email>kohne@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

